PMV Pharmaceuticals, Inc.
PMVP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $1 | $1 | $1 |
| Gross Profit | -$1 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |
| R&D Expenses | $57 | $55 | $52 | $36 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $27 | $24 | $25 | $21 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $84 | $79 | $76 | $57 |
| Operating Income | -$85 | -$80 | -$77 | -$58 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $11 | $11 | $4 | $0 |
| Pre-Tax Income | -$75 | -$69 | -$73 | -$58 |
| Tax Expense | -$16 | $0 | -$0 | $0 |
| Net Income | -$59 | -$69 | -$73 | -$58 |
| % Margin | – | – | – | – |
| EPS | -1.138 | -1.44 | -1.61 | -1.28 |
| % Growth | 21% | 10.6% | -25.8% | – |
| EPS Diluted | -1.138 | -1.44 | -1.61 | -1.28 |
| Weighted Avg Shares Out | 52 | 48 | 46 | 45 |
| Weighted Avg Shares Out Dil | 52 | 48 | 46 | 45 |
| Supplemental Information | – | – | – | – |
| Interest Income | $11 | $11 | $4 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$74 | -$68 | -$73 | -$57 |
| % Margin | – | – | – | – |